Company

Aposcience AG is a biopharmaceutical company established in 2008 and headquartered in Vienna.

The company is developing innovative therapeutics for regenerative medicine that are based on secretomes of white blood cells isolated from peripheral blood. This approach sets Aposcience apart from the significant number of competitors working on stem cell based approaches. It is in tune with the generally accepted notion that stem cells exert their beneficial effects by paracrine signaling, not by rebuilding tissue per se. In contrast to competitors in the field, the company utilizes for APOSECTM production easily obtainable peripheral blood mononuclear cells as compared to stem cells or stem cell-derived secretomes from bone marrow.

A priority for management and shareholders is the development of a validated manufacturing process for its advanced therapeutic products, and a subsequent clinical proof of concept trial in wound healing.

The current lead product APO-1 (APOSECTM) consists of a complex mixture of cytokines and other proteins and factors, which act synergistically to be both anti-inflammatory and pro-angiogenic. It is indicated for diseases where wound healing is impaired or adverse tissue remodeling needs to be prohibited. These include cutaneous wound healing in conditions like diabetic foot ulcer, ischemic ulceration in smokers and pressure wounds in immobilized patients. Furthermore, APO-1 (APOSECTM) is also indicated for defects caused by ischemia/reperfusion of internal organs, e.g., myocardial infarction (MI) as well as stroke or spinal cord injury. The company seeks partners, specifically among companies with a franchise of blood derived products, who would be interested in co-developing its therapeutic assets.

Additionally, in order to broaden the validity of their biomarker studies, the company identifies clinical trials performed by key opinion leaders in chronic obstructive pulmonary disease (COPD) research to validate their proprietary HSP27-marker in lung diseases (COPD and lung cancer).

Latest News
Mar
31

MarsyasI - clinical phase 1 study completed

[more]

Nov
24

Paper on content analysis of APOSEC recently published

[more]